Market Performance
Rubicon Research made a powerful entrance into the stock market, opening 28% higher than its IPO price.
- NSE Listing Price: ₹620 per share
- BSE Listing Price: ₹620.10 per share
- Issue Price: ₹485 per share
- Listing Premium: Around 27.8%
- Market Capitalisation on Debut: ₹10,216 crore
The listing sparked interest across Dalal Street, thanks to the strong response the company received during the IPO phase.
Main News: Rubicon Research IPO Listing Day Highlights
Rubicon Research’s entry into the listed space follows an overwhelming investor response, with the IPO getting subscribed 48 times between October 9 and October 13.
The non-institutional investor category took the lead, subscribing to over 80 times of their allotted quota, reflecting heavy participation from high-net-worth individuals.
Rubicon Research IPO Structure
The total IPO size stood at ₹1,377.50 crore, split between a fresh issue and an offer for sale:
- Fresh Issue: ₹500 crore
- Offer for Sale (OFS): ₹877.5 crore by promoter entity
- Price Band: ₹461–₹485 per share
The strong demand in the subscription phase translated into a decisive listing day performance.
Company Details
Rubicon Research operates in the pharmaceutical formulations segment and has created a market presence with a product portfolio largely focused on regulated markets.
The proceeds from the fresh issue of ₹500 crore are earmarked for:
- ₹310 crore towards repayment of borrowings
- Remaining funds assigned for inorganic growth and general corporate purposes
Summary
The Rubicon Research listing turned heads with a 28% premium debut, positioning it among the stronger IPO listings in recent months.
With ₹620+ opening levels across both NSE and BSE, the stock reflected high investor confidence and liquidity support from the subscription phase.
For investors tracking IPO news, market listings and debut performance, Rubicon’s entry sets a noteworthy benchmark for upcoming issues in the pharma segment.
Easy & quick
Leave A Comment?